Please use this identifier to cite or link to this item:
https://observatorio.fm.usp.br/handle/OPI/24196
Title: | Factors Associated with Long-Term Risk of Relapse after Unrelated Cord Blood Transplantation in Children with Acute Lymphoblastic Leukemia in Remission |
Authors: | PAGE, Kristin M.; LABOPIN, Myriam; RUGGERI, Annalisa; MICHEL, Gerard; HEREDIA, Cristina Diaz de; O'BRIEN, Tracey; PICARDI, Alessandra; AYAS, Mouhab; BITTENCOURT, Henrique; VORA, Ajay J.; TROY, Jesse; BONFIM, Carmen; VOLT, Fernanda; GLUCKMAN, Eliane; BADER, Peter; KURTZBERG, Joanne; ROCHA, Vanderson |
Citation: | BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, v.23, n.8, p.1350-1358, 2017 |
Abstract: | For pediatric patients with acute lymphoblastic leukemia (ALL), relapse is an important cause of treatment failure after unrelated cord blood transplant (UCBT). Compared with other donor sources, relapse is similar or even reduced after UCBT despite less graft-versus-host disease (GVHD). We performed a retrospective analysis to identify risk factors associated with the 5-year cumulative incidence of relapse after UCBT. In this retrospective, registry-based study, we examined the outcomes of 640 children (<18 years) with ALL in first complete remission (CR1; n = 257, 40%) or second complete remission (CR2; n = 383, 60%) who received myeloablative conditioning followed by a single-unit UCBT from 2000 to 2012. Most received antithymocyte globulin (88%) or total body irradiation (TBI; 69%), and cord blood grafts were primarily mismatched at 1 (50%) or 2(+) (34%) HLA loci. Considering patients in CR1, the rates of 5-year overall survival (OS), leukemia-free survival (LFS), and relapse were 59%, 52%, and 23%, respectively. In multivariate analysis (MVA), acute GVHD (grades II to IV) and TBI protected against relapse. In patients in CR2, rates of 5-year OS, LFS, and the cumulative incidence of relapse were 46%, 44%, and 28%, respectively. In MVA, longer duration from diagnosis to UCBT >= 30 months) and TBI were associated with decreased relapse risk. Importantly, receiving a fully HLA matched graft was a strong risk factor for increased relapse in MVA. An exploratory analysis of all 640 patients supported the important association between the presence of acute GVHD and less relapse but also demonstrated an increased risk of nonrelapse mortality. In conclusion, the impact of GVHD as a graft-versus-leukemia marker is evident in pediatric ALL after UCBT. Strategies that promote graft-versus-leukemia while harnessing GVHD should be further investigated. (C) 2017 American Society for Blood and Marrow Transplantation. |
Appears in Collections: | Artigos e Materiais de Revistas Científicas - FM/MCM Artigos e Materiais de Revistas Científicas - HC/ICHC Artigos e Materiais de Revistas Científicas - LIM/31 Artigos e Materiais de Revistas Científicas - ODS/03 |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
art_PAGE_Factors_Associated_with_LongTerm_Risk_of_Relapse_after_2017.PDF Restricted Access | publishedVersion (English) | 641.44 kB | Adobe PDF | View/Open Request a copy |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.